April 16, 2025; Boise, IDAHO — The Fatty Liver Foundation (FLF) today announces the launch of the fourth annual "The State of Steatotic (Fatty) Liver Care in America: Patient Perspectives Research", a nationwide survey designed to capture the lived experiences of individuals affected by metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-associated forms of steatotic liver disease.
This year’s survey arrives at a pivotal moment. With Rezdiffra™, the first FDA-approved treatment for MASH, now in use for over a year, and broader adoption of non-invasive tests (NITs) underway in clinical settings, patients are navigating a rapidly evolving landscape. Public awareness efforts—ranging from online education to direct-to-consumer campaigns—have begun to spotlight liver health, while alcohol-associated liver disease (ALD) and the emerging metabolic dysfunction-associated ALD (MetALD) subtype are finally gaining overdue recognition, though gaps persist.
“With a treatment now available and more tools in our diagnostic toolkit, we must ask—how are these advances reaching patients?” said Wayne Eskridge, Founder and CEO of FLF. “Our survey gives voice to the people living with these complex conditions, so we can better measure progress and push for equitable, comprehensive liver care.”
The confidential, multilingual survey—available in English, Spanish, Mandarin, and Vietnamese—collects first-hand information from adult respondents across the U.S. on topics ranging from diagnosis experiences and access to specialists, to emotional well-being, care satisfaction, and awareness of treatment options. This year’s expanded language access is part of FLF’s ongoing commitment to reaching underserved communities and ensuring inclusive representation in liver health research.
“Patients are the ultimate stakeholders. Their input is crucial as we evaluate the real-world application of therapeutic and diagnostic advances,” said Dr. Neeraj Mistry, Chief Medical Officer at FLF. “This data will help inform actionable strategies to reduce disease burden and improve quality of life for people living with steatotic liver disease.”
Now in its fourth year, the survey continues to fill a critical gap in understanding how healthcare systems, providers, and policy are—or aren’t—meeting the needs of this diverse patient population.
“For far too long, people living with alcohol-associated liver disease or navigating transplant due to alcohol have felt invisible,” said Jenn Jones, Founder and Visionary of Sober Livers, an FLF impact program. “This survey recognizes all subtypes of steatotic liver disease and creates space for every voice—especially those often left out.”
The initiative has also become a valuable tool in shaping broader public health priorities. “We are proud to launch this survey for the fourth consecutive year,” said Henry E. Chang, Executive Director of FLF. “It’s a powerful instrument for tracking year-over-year trends and ensuring that progress on paper translates into meaningful change in patients’ lives.”
To participate in the 2025 survey or learn more about the initiative, visit www.fattyliverfoundation.org or email [email protected].
About the Fatty Liver Foundation
The Fatty Liver Foundation is a national non-profit patient organization dedicated to improving the identification, diagnosis, treatment, and support of individuals living with steatotic (fatty) liver disease, including MASLD, MASH, and alcohol-associated conditions. Through awareness, screening, education, and advocacy, FLF works to ensure that every person—regardless of where they live or their ability to pay—can access the care and support they need to live well with liver disease. Connect with us at www.fattyliverfoundation.org, Facebook (Fatty Liver Foundation JUST LIVER NEWS), X (@LiverSaver), and YouTube (@Fatty Liver Foundation).
About Sober Livers
Sober Livers, an impact program of FLF, empowers individuals diagnosed with alcohol-associated liver disease and those navigating recovery after transplant to discover and embrace their personal alcohol recovery journey while managing the complexities of liver disease. Learn more at www.soberlivers.org.
Media Contact:
Henry E. Chang
Executive Director
Fatty Liver Foundation
Mobile: +1 917-400-8900
Email: [email protected]
# # #
